SG Americas Securities LLC Decreases Position in Haemonetics Corporation $HAE

Posted by on Jul 11th, 2026

SG Americas Securities LLC decreased its holdings in Haemonetics Corporation (NYSE:HAE – Free Report) by 68.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,540 shares of the medical instruments supplier’s stock after selling 9,679 shares during the period. SG Americas Securities LLC’s holdings in Haemonetics were worth $256,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after purchasing an additional 971 shares during the period. Caxton Associates LLP purchased a new stake in Haemonetics during the 1st quarter worth about $216,000. United Services Automobile Association purchased a new stake in Haemonetics during the 1st quarter worth about $212,000. Empowered Funds LLC raised its position in Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after purchasing an additional 9,051 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 1.4%

Shares of NYSE HAE opened at $76.05 on Friday. The business has a 50-day moving average of $68.35 and a two-hundred day moving average of $66.36. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 1.51 and a beta of 0.52. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87.

Haemonetics (NYSE:HAE – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the prior year, the business posted $1.24 EPS. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, analysts forecast that Haemonetics Corporation will post 5.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on HAE shares. BTIG Research reissued a “buy” rating and set a $84.00 price objective on shares of Haemonetics in a research report on Friday, June 26th. JPMorgan Chase & Co. reduced their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Barrington Research decreased their price target on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a report on Friday, May 8th. Finally, Mizuho increased their price objective on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $78.33.

Read Our Latest Stock Report on Haemonetics

Haemonetics Profile

(Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Featured Stories

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.